NTRK1 and ovarian carcinoma: To investigate the relative importance of cell-surface receptor tyrosine kinase expression to chemotherapy sensitivity in ovarian cancer, we determined the proliferation response to cisplatin or paclitaxel (Fig. 1A) across a panel of fifteen ovarian cancer cell lines.